Pre Seed · Biotech · Copenhagen, Denmark · Founded 2022 · 10–10 employees
Fuse Vectors has developed a breakthrough cell-free platform for manufacturing AAV vectors used in gene therapy, replacing outdated 1980s cell-based methods with precise enzymatic processes. The company's technology delivers over 99% filled capsids with enhanced quality and scalability, reducing production time from weeks to hours. Founded in 2022 by Benjamin Blaha, Jordan Turnbull, and Henrik Stage, the startup secured €4.9 million in pre-seed funding led by HCVC in February 2025. They are currently collaborating with over half a dozen partners including academic research groups and leading pharmaceutical companies, positioning themselves as a universal solution for AAV gene therapy development.
No open roles listed right now.